Clearance of von Willebrand factor

Thrombosis and Haemostasis

Volumn 99, Issue 2, 2008, Pages 271-278

  Denis, Cécile V ^a,b   Christophe, Olivier D ^a,b   Oortwijn, Beatrijs D ^c   Lenting, Peter J ^c,d  

^a Dept Environ Med Natl Inst Publ HIth   (Norway)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d CRUCELL HOLLAND BV   (Netherlands)

Author keywords

Animal models; Factor VIII; Von Willebrand disease; Von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

CATABOLISM; CHEMICAL MODEL; ENDOTHELIUM CELL; GENE EXPRESSION; GLYCOSYLATION; HALF LIFE TIME; HEMOPHILIA A; HUMAN; MEGAKARYOCYTE; MISSENSE MUTATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; REVIEW; SIALYLATION; VON WILLEBRAND DISEASE;

ANIMALS; BLOOD GROUP ANTIGENS; COAGULANTS; DRUG THERAPY, COMBINATION; ENDOTHELIAL CELLS; FACTOR VIII; GLYCOSYLATION; HALF-LIFE; HEMOPHILIA A; HUMANS; MEGAKARYOCYTES; PEPTIDE HYDROLASES; PLATELET MEMBRANE GLYCOPROTEINS; POLYETHYLENE GLYCOLS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, CELL SURFACE; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 38949166825     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-10-0629     Document Type: Review

References (85)

1. Zlokovic BV. Clearing amyloid through the blood-brain barrier. J Neurochem 2004; 89: 807-811.
2. Sagare A, Deane R, Bell RD, et al. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med 2007; 13: 1029-1031.
3. Pullinger CR, Kane JP, Malloy MJ. Primary hypercholesterolemia: genetic causes and treatment of five monogenic disorders. Expert Rev Cardiovasc Ther 2003; 1: 107-119.
4. Ruggeri ZM. Von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost 2003; 1: 1335-1342.
5. Haberichter SL, Merricks EP, Fahs SA, et al. Reestablishment of VWF-dependent Weibel-Palade bodies in VWD endothelial cells. Blood 2005; 105: 145-152.
6. Vischer UM, Wagner DD. von Willebrand factor proteolytic processing and multimerization precede the formation of Weibel-Palade bodies. Blood 1994; 83: 3536-3544.
7. Michaux G, Cutler DF. How to roll an endothelial cigar: the biogenesis of Weibel-Palade bodies. Traffic 2004; 5: 69-78.
8. Rondaij MG, Bierings R, Kragt A, et al. Dynamics and plasticity of Weibel-Palade bodies in endothelial cells. Arterioscler Thromb Vasc Biol 2006; 26: 1002-1007.
9. Terraube V, Pendu R, Baruch D, et al. Increased metastatic potential of tumor cells in von Willebrand factor-deficient mice. J Thromb Haemost 2006; 4: 519-526.
10. O'Seaghdha M, van Schooten CJ, Kerrigan SW, et al. Staphylococcus aureus protein A binding to von Willebrand factor A1 domain is mediated by conserved IgG binding regions. FEBS J 2006; 273: 4831-4841.
11. Pawar P, Shin PK, Mousa SA, et al. Fluid shear regulates the kinetics and receptor specificity of Staphylococcus aureus binding to activated platelets. J Immunol 2004; 173: 1258-1265.
12. Hartleib J, Kohler N, Dickinson RB, et al. Protein A is the von Willebrand factor binding protein on Staphylococcus aureus. Blood 2000; 96: 2149-2156.
13. Qin F, Impeduglia T, Schaffer P, et al. Overexpression of von Willebrand factor is an independent risk factor for pathogenesis of intimal hyperplasia: preliminary studies. J Vasc Surg 2003; 37: 433-439.
14. Pendu R, Terraube V, Christophe OD, et al. P-selectin glycoprotein ligand 1 and beta2-integrins cooperate in the adhesion of leukocytes to von Willebrand factor. Blood 2006; 108: 3746-3752.
15. Zannettino AC, Holding CA, Diamond P, et al. Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol 2005; 204: 714-723.
16. Shahbazi S, Lenting PJ, Fribourg C, et al. Characterization of the interaction between von Willebrand factor and osteoprotegerin. J Thromb Haemost 2007; 5: 1956-1962.
17. Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood 1998; 92: 3983-3996.
18. Graw J, Brackmann HH, Oldenburg J, et al. Haemophilia A: from mutation analysis to new therapies. Nat Rev Genet 2005; 6: 488-501.
19. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998; 67: 395-424.
20. Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol 1990; 6: 217-246.
21. Piovella F, Ascari E, Sitar GM, et al. Immunofluorescent detection of factor VIII-related antigen in human platelets and megakaryoctes. Haemostasis 1974; 3: 288-295.
22. Wagner DD, Mayadas T, Marder VJ. Initial glycosylation and acidic pH in the Golgi apparatus are required for multimerization of von Willebrand factor. J Cell Biol 1986; 102: 1320-1324.
23. van Schooten CJ, Tjernberg P, Westein E, et al. Cysteine-mutations in von Willebrand factor associated with increased clearance. J Thromb Haemost 2005; 3: 2228-2237.
24. Bierings R, van den Biggelaar M, Kragt A, et al. Efficiency of von Willebrand factor-mediated targeting of IL-8 into Weibel-Palade bodies. J Thromb Haemost 2007; 5: 2512-2519.
25. van de Ven WJ, Voorberg J, Fontijn R, et al. Furin is a subtilisin-like proprotein processing enzyme in higher eukaryotes. Mol Biol Rep 1990; 14: 265-275.
26. Casonato A, Pontara E, Sartorello F, et al. Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. Blood 2002; 99: 180-184.
27. Hilbert L, Nurden P, Caron C, et al. Type 2N von Willebrand disease due to compound heterozygosity for R854Q and a novel R763G mutation at the cleavage site of von Willebrand factor propeptide. Thromb Haemost 2006; 96: 290-294.
28. Denis C, Methia N, Frenette PS, et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci USA 1998; 95: 9524-9529.
29. Titani K, Kumar S, Takio K, et al. Amino acid sequence of human von Willebrand factor. Biochemistry 1986; 25: 3171-3184.
30. Matsui T, Titani K, Mizuochi T. Structures of the asparagine-linked oligosaccharide chains of human von Willebrand factor. Occurrence of blood group A, B, and H(O) structures. J Biol Chem 1992; 267: 8723-8731.
31. Sodetz JM, Paulson JC, McKee PA. Carbohydrate composition and identification of blood group A, B, and H oligosaccharide structures on human Factor VIII/von Willebrand factor. J Biol Chem 1979; 254: 10754-10760.
32. Samor B, Michalski JC, Mazurier C, et al. Primary structure of the major O-glycosidically linked carbohydrate unit of human von Willebrand factor. Glycoconj J 1989; 6: 263-270.
33. Millar CM, Brown SA. Oligosaccharide structures of von Willebrand factor and their potential role in von Willebrand disease. Blood Rev 2006; 20: 83-92.
34. Jenkins PV, O'Donnell JS. ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? Transfusion 2006; 46: 1836-1844.
35. McCallum CJ, Peake IR, Newcombe RG, Bloom AL. Factor VIII levels and blood group antigens. Thromb Haemost 1983; 50: 757.
36. O'Donnell JS, McKinnon TA, Crawley JT, Lane DA, Laffan MA. Bombay phenotype is associated with reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysis. Blood 2005; 106: 1988-1991.
37. O'Donnell J, Boulton FE, Manning RA, Laffan MA. Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels. Arterioscler Thromb Vasc Biol 2002; 22: 335-341.
38. Morelli VM, de Visser MC, Van Tilburg NH, et al. ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens. Thromb Haemost 2007; 97: 534-541.
39. O'Donnell J, Mille-Baker B, Laffan M. Human umbilical vein endothelial cells differ from other endothelial cells in failing to express ABO blood group antigens. J Vasc Res 2000; 37: 540-547.
40. O'Donnell J, Laffan MA. Dissociation of ABH antigen expression from von Willebrand factor synthesis in endothelial cell lines. Br J Haematol 2003; 121: 928-931.
41. Sweeney JD, Hoernig LA. Intraplatelet von Willebrand factor and ABO blood group. Thromb Res 1992; 68: 393-398.
42. Brown SA, Eldridge A, Collins PW, et al. Increased clearance of von Willebrand factor antigen post-DDAVP in Type 1 von Willebrand disease: is it a potential pathogenic process? J Thromb Haemost 2003; 1: 1714-1717.
43. Gallinaro L, Cattini MG, Bertomoro A, et al. How ABO blood groups affect von Willebrand factor levels in normal subjects. J Thromb Haemost 2007; 5 (Suppl 1): P-T-200.
44. Borchiellini A, Fijnvandraat K, ten Cate JW, et al. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood 1996; 88: 2951-2958.
45. Haberichter SL, Balistreri M, Christopherson P, et al. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood 2006; 108: 3344-3351.
46. Nossent AY, Van Marion V, Van Tilburg NH, et al. von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis. J Thromb Haemost 2006; 4: 2556-2562.
47. Fijnvandraat K, Peters M, ten Cate JW. Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels. Br J Haematol 1995; 91: 474-476.
48. Vlot AJ, Mauser-Bunschoten EP, Zarkova AG, et al. The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A. Thromb Haemost 2000; 83: 65-69.
49. Plaimauer B, Schlokat U, Turecek PL, et al. Recombinant von Willebrand factor: preclinical development. Semin Thromb Hemost 2001; 27: 395-403.
50. O'Donnell J, Boulton FE, Manning RA, et al. Genotype at the secretor blood group locus is a determinant of plasma von Willebrand factor level. Br J Haematol 2002; 116: 350-356.
51. Sodetz JM, Pizzo SV, McKee PA. Relationship of sialic acid to function and in vivo survival of human factor VIII/von Willebrand factor protein. J Biol Chem 1977; 252: 5538-5546.
52. Ellies LG, Ditto D, Levy GG, et al. Sialyltransferase ST3Gal-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligands. Proc Natl Acad Sci USA 2002; 99: 10042-10047.
53. Millar CM, Riddel AF, Brown SA. Quantitation of Binding of Ricinus communis Agglutinin I to Von Willebrand Factor (VWF): Investigation of Relationship with Plasma Clearance of VWF in Type 1 Von Willebrand Disease. ASH Annual Meeting Abstracts 2005; 106: 727.
54. Sweeney JD, Novak EK, Reddington M, Takeuchi KH, Swank RT. The RIIIS/J inbred mouse strain as a model for von Willebrand disease. Blood 1990; 76: 2258-2265.
55. Mohlke KL, Nichols WC, Westrick RJ, et al. A novel modifier gene for plasma von Willebrand factor level maps to distal mouse chromosome 11. Proc Natl Acad Sci USA 1996; 93: 15352-15357.
56. Morange PE, Tregouet DA, Frere C, et al. Biological and genetic factors influencing plasma factor VIII levels in a healthy family population: results from the Stanislas cohort. Br J Haematol 2005; 128: 91-99.
57. Smith PL, Lowe JB. Molecular cloning of a murine N-acetylgalactosamine transferase cDNA that determines expression of the T lymphocyte-specific CT oligosaccharide differentiation antigen. J Biol Chem 1994; 269: 15162-15171.
58. Mohlke KL, Purkayastha AA, Westrick RJ, et al. Mvwf, a dominant modifier of murine von Willebrand factor, results from altered lineage-specific expression of a glycosyltransferase. Cell 1999; 96: 111-120.
59. Carew JA, Quinn SM, Stoddart JH, Lynch DC. O-linked carbohydrate of recombinant von Willebrand factor influences ristocetin-induced binding to platelet glycoprotein 1b. J Clin Invest 1992; 90: 2258-2267.
60. Schulte am Esch J, Robson SC, Knoefel WT, et al. Impact of O-linked glycosylation of the VWF-A1-domain flanking regions on platelet interaction. Br J Haematol 2005; 128: 82-90.
61. Stoddart JH, Jr., Andersen J, Lynch DC. Clearance of normal and type 2A von Willebrand factor in the rat. Blood 1996; 88: 1692-1699.
62. Matsui T, Hamako J, Ozeki Y, et al. Comparative study of blood group-recognizing lectins toward ABO blood group antigens on neoglycoproteins, glycopro-teins and complex-type oligosaccharides. Biochim Biophys Acta 2001; 1525: 50-57.
63. van Schooten CJ, Denis CV, Lisman T, et al. Variations in glycosylation of von Willebrand factor with O-linked sialylated T-antigen are associated with its plasma levels. Blood 2006; 109: 2430-2437.
64. Dent JA, Galbusera M, Ruggeri ZM. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit. J Clin Invest 1991; 88: 774-782.
65. Furlan M, Robles R, Lamie B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87: 4223-4234.
66. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87: 4235-4244.
67. Bowen DJ. Genome-wide linkage analysis of von Willebrand factor plasma levels implicates the ABO locus as a principal determinant: should we overlook ADAMTS13? Thromb Haemost 2003; 90: 961.
68. Millar CM, Starke R, Riddel AF, et al. Investigation of relationship between ADAMTS-13, von Willebrand factor antigen and collagen-binding activity in patients with type 1 von Willebrand disease. J Thromb Haemost 2005; 3 (Suppl 1): P1471.
69. Lenting PJ, van Schooten CJ, Denis CV. Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost 2007; 5: 1353-1360.
70. Lenting PJ, Westein E, Terraube V, et al. An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation. J Biol Chem 2004; 279: 12102-12109.
71. van Schooten CJ, Denis CV, Oortwijn BD, et al. Liver and spleen macrophages contribute to the clearance of von Willebrand factor and its complex with factor VIII. J Thromb Haemost 2007; 5 (Suppl 1): O-W-017.
72. Schneider SW, Nuschele S, Wixforth A, et al. Shear-induced unfolding triggers adhesion of von Willebrand factor fibers. Proc Natl Acad Sci USA 2007; 104: 7899-7903.
73. Murphy JE, Pan C, Barnett T, et al. Site-specific pegylation of rFVIII results in prolonged in vivo efficacy. J Thromb Haemost 2007; 5 (Suppl 1): P-T-022.
74. Regan L, Jiang X, Ramsey P, et al. Biological activity of pegylated factor VIII. J Thromb Haemost 2007; 5 (Suppl 1): P-T-026 .
75. Noe DA. A mathematical model of coagulation factor VIII kinetics. Haemostasis 1996; 26: 289-303.
76. Schambeck CM, Grossmann R, Zonnur S, et al. High factor VIII (FVIII) levels in venous thromboembolism: role of unbound FVIII. Thromb Haemost 2004; 92: 42-46.
77. Lollar P, Parker CG. Stoichiometry of the porcine factor VIII-von Willebrand factor association. J Biol Chem 1987; 262: 17572-17576.
78. Leyte A, Verbeet MP, Brodniewicz-Proba T, et al. The interaction between human blood-coagulation factor VIII and von Willebrand factor. Characterization of a high-affinity binding site on factor VIII. Biochem J 1989; 257: 679-683.
79. Turecek PL, Scheiflinger F, Siekmann J, et al. Biochemical and functional characterization of chemically modified recombinant von Willebrand factor (rVWF) as a carrier prolonging survival of rFVIII in hemophilia A knock-out mice. J Thromb Haemost 2007; 5 (Suppl 1): O-M-018.
80. Turecek PL, Siekmann J, Weber A, et al. Modification of rVWF with polysialic acid: Biochemical and functional characterization in mice with VWD. ASH Annual Meeting Abstracts 2006; 108: 1001.
81. Hermeling S, Crommelin DJ, Schellekens H, et al. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 2004; 21: 897-903.
82. Molineux G. Pegylation: engineering improved biopharmaceuticals for oncology. Pharmacotherapy 2003; 23: 3S-8S.
83. Tang L, Pan C, Atwal H, et al. Pegylation protects factor VIII from the inhibition of antibody inhibitors. J Thromb Haemost 2007; 5 (Suppl 1): P-T-036.
84. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002; 100: 3457-3469.
85. van Dijk K, van der Bom JG, Lenting PJ, et al. Factor VIII half-life and clinical phenotype of severe hemophilia A. Haematologica 2005; 90: 494-498.